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Abstract
Background: A large number of gene expression profiling (GEP) studies on prognosis of colorectal cancer (CRC) has been
performed, but no reliable gene signature for prediction of CRC prognosis has been found. Bioinformatic enrichment tools
are a powerful approach to identify biological processes in high-throughput data analysis.
Principal Findings: We have for the first time collected the results from the 23 so far published independent GEP studies on
CRC prognosis. In these 23 studies, 1475 unique, mapped genes were identified, from which 124 (8.4%) were reported in at
least two studies, with 54 of them showing consisting direction in expression change between the single studies. Using
these data, we attempted to overcome the lack of reproducibility observed in the genes reported in individual GEP studies
by carrying out a pathway-based enrichment analysis. We used up to ten tools for overrepresentation analysis of Gene
Ontology (GO) categories or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in each of the three gene lists
(1475, 124 and 54 genes). This strategy, based on testing multiple tools, allowed us to identify the oxidative
phosphorylation chain and the extracellular matrix receptor interaction categories, as well as a general category related to
cell proliferation and apoptosis, as the only significantly and consistently overrepresented pathways in the three gene lists,
which were reported by several enrichment tools.
Conclusions: Our pathway-based enrichment analysis of 23 independent gene expression profiling studies on prognosis of
CRC identified significantly and consistently overrepresented prognostic categories for CRC. These overrepresented
categories have been functionally clearly related with cancer progression, and deserve further investigation.
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Introduction
Colorectal cancer (CRC) is the third most common cancer and
the fourth-leading cause of cancer death worldwide, with a lifetime
risk in Western European and North American populations
around 5% [1].
Many gene expression profiling (GEP) studies on CRC have
been performed in the last decade using microarray technology.
According to their potential clinical applications, they can be
classified into three groups [2]: studies on carcinogenesis process,
studies on prognosis prediction, and studies on treatment response
prediction. They show little overlap in the identified genes, and no
reliable signature useful in clinical practice has been found.
Currently, the International Union Against Cancer (UICC) TNM
classification of malignant tumours based on clinicopathological
staging remains the standard for CRC prognostication [3].
We focused on the studies on prognosis prediction, which
comprise a heterogeneous group of GEP studies. They aim to
identify a gene expression profile to discriminate more aggressive
from less aggressive CRC, based on different features related to
disease progression, such as the existence of recurrence, the
presence of metastasis, or survival data. To date, only one meta-
analysis of ten GEP studies has reported a list of 13 genes
differentially expressed in CRC with good versus bad prognosis,
reported by at least two independent studies [4].
Multiple reasons have been proposed to explain this lack of
reproducibility in the GEP studies on CRC, such as underpow-
ered studies, lack of validation of results, differences in experi-
mental protocol and statistical pitfalls in analysing microarray
expression data for cancer outcome [3]. Changes in biological
characteristics require coordinated variation in expression of gene
sets which regulate biological activity, and this information can
hardly be extracted from changes in expression of individual
genes when overlapping among studies is so low [5]. Enrichment
analysis tools, which estimate overrepresentation of particular
gene categories or pathways in a gene list, are a promising
strategy to identify biological categories implicated in the
investigated process [6].
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tools has recently been published [6]. Based on the algorithm
applied, the enrichment tools can be classified into three classes:
singular enrichment analysis (SEA or class I); gene set enrichment
analysis (GSEA or class II); and modular enrichment analysis
(MEA or class III). In all tools, the input list of genes is mapped to
the biological terms in databases, and then statistical analysis
examines the enrichment of gene members for each of the
annotation terms and corrects for multiple testing [6]. We applied
several SEA tools for the same input gene lists, and only enriched
categories obtained with several tools were considered indicative of
genuine prediction. This strategy, based on testing multiple tools,
is recommended in order to obtain the most satisfactory results [7].
Gene Ontology (GO) [8] and Kyoto Encyclopedia of Genes and
Genomes (KEGG) [9] are the two main annotation databases
collecting biological knowledge of genes, which make them very
suitable for bioinformatics scanning for enrichment analysis [6].
Currently, GO contains information for 18261 human gene
products, while KEGG maps 373 different pathways. Our goal
was to identify the functional categories (GO terms and KEGG
pathways) that are consistently overrepresented in a statistically
significant way in the list of differentially expressed genes inferred
from the GEP studies on CRC prognosis. We first collected data
from the 23 published independent GEP studies on prognosis of
CRC to extract the genes reported in at least two of them, and
then these genes were used for the systematic enrichment analysis
with several independent SEA tools. This way, we overcame the
lack of reproducibility observed in both the genes reported in
individual GEP studies and the overrepresented categories
reported by enrichment analysis tools, and could identify
consistently enriched categories.
Results
Meta-analysis of the GEP studies
A total of 1897 different gene identifiers (IDs) were reported to
be differentially expressed in the 23 independent GEP studies on
prognosis of CRC (Table 1). From them, the number of unique,
mapped genes was 1475, of which 603 genes were up-regulated
and 794 down-regulated in poor prognosis samples, while 78 had
an opposite direction in expression change between single studies.
From the 1475 genes, 124 genes (8.4%) were reported in more
than one GEP study (115 in two, and nine in three studies), 19 of
them (15.3%) were up-regulated in poor prognosis samples in two
studies, 35 down-regulated (28.2%), and 70 with contrasting
direction in expression change between two studies. Thus, 54 out
of the 124 genes (43.5%) reported the same direction in gene
expression change in two different GEP studies. From the nine
genes reported in three studies (ATP5C1, CA2, CYP51A1, FN1,
HSP90AB1, IQGAP1, RPS5, SPP1, and TXN), only CYP51A1
and SPP1 showed the same direction in expression change in all
three studies (Table S1). All these nine genes were included in the
54 gene list. There was no tendency of the genes reported by two
studies to come up more frequently from two GEP studies
investigating the same feature related to disease prognosis
(existence of recurrence, presence of metastasis or survival) than
from any two studies. The seven studies investigating recurrence
reported 541 unique genes, 15 of them (2.8%) in two studies. The
13 studies related to metastasis reported 934 unique genes, with 50
of them (5.3%) in two studies. Finally, the two studies related to
survival reported 34 unique genes, none of them common for both
studies.
See Table S1 and Table S2 for a complete list of genes.
Enrichment analyses
Three gene lists were used for the enrichment analyses: all 1475
genes reported in the 23 independent GEP studies, the 124 genes
reported in at least two GEP studies (independently of consistence
in expression change between studies), and the 54 genes reported
in at least two GEP studies with consistent direction in gene
expression change between samples with poor and good prognosis.
Ten enrichment tools were used to obtain significantly overrep-
resented GO Biological Process, GO Molecular Function
categories, and KEGG pathways (Tables S3, S4, S5).
The number of reported enriched categories showed a
considerable variability among the different tools used (Table 2),
although the same significance threshold (P value,0.05 after
correction for multiple testing) and analysis conditions (whole
genome as reference background and at least two genes from the
input list in the enriched category) were applied in all analyses.
The resulted P values for enrichment of a single GO or KEGG
term often ranged several orders of magnitude between the
different tools (Tables S3, S4, S5). In general, the tools GeneCodis
[10] and WebGestalt [11] reported more enriched categories than
the other tools, and many of the enriched categories were reported
only by GeneCodis (Tables S3, S4, S5). GeneCodis also classified a
significantly lower number of genes from the input list in the
reported enriched GO categories. On the other hand, the
GATHER tool [12] reported less enriched categories than the
other tools (Table 2).
Identification of consistently enriched categories
Despite the variation in the number of overrepresented
categories reported by the different enrichment tools, several
categories were reported by many of the tools used. To avoid false
positives, we applied two stringent selection thresholds before we
considered a category as consistently enriched. First, only the
categories reported to be enriched by several tools in a gene list
were selected (Table S6). From them, only the categories common
in at least two of the three gene lists were considered to be
consistently enriched. Using these two selection criteria, six general
GO Biological Process categories (cell proliferation, positive
regulation of biological process, positive regulation of cellular
process, regulation of apoptosis, regulation of cell proliferation,
and response to chemical stimulus), five GO Molecular Function
categories (hydrogen ion transmembrane transporter activity,
inorganic cation transmembrane transporter activity, monovalent
inorganic cation transmembrane transporter activity, protein
binding, and unfolded protein binding), and seven KEGG
pathways (extracellular matrix receptor interaction, focal adhe-
sion, Huntington’s disease, oxidative phosphorylation, pathways in
cancer, Parkinson’s disease, and small cell lung cancer) were
consistently overrepresented in the GEP studies on prognosis of
CRC (Table 3). The proportion of up- and down-regulated genes
was similar within each of the consistently enriched GO and
KEGG categories, as in the 124 gene list (data not shown). The
ratio of enrichment was higher for the more specific and well-
defined KEGG pathways than for the broad GO categories
(Figure 1). A high overlap of the individual genes between these 18
categories was also observed (Table 4). Based on this overlap, three
biologically meaningful individual category groups were finally
obtained:
a) A large group including the six general GO Biological Process
categories (cell proliferation, positive regulation of biological
process, positive regulation of cellular process, regulation of
apoptosis, regulation of cell proliferation, and response to
chemical stimulus), together with the two GO Molecular
Enrichment Analysis GEP Studies Prognosis CRC
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binding. The KEGG category pathways in cancer also
overlap with these GO categories.
b) The three KEGG pathways oxidative phosphorylation,
Huntington’s disease and Parkinson’s disease, together with
three GO Molecular Function categories (hydrogen ion
transmembrane transporter activity, inorganic cation trans-
membrane transporter activity, and monovalent inorganic
cation transmembrane transporter activity), which include
four to six common genes.
c) The two KEGG pathways extracellular matrix receptor
interaction and focal adhesion, with all six genes in these two
KEGG categories also included in the large GO Molecular
Function category protein binding.
Enrichment analysis using the Ingenuity software confirmed the
results obtained with the GO and KEGG databases. The only
overrepresented canonical pathway in the 124 gene list was
oxidative phosphorylation (Pcorrected=2.7610
22), while this cate-
gory was the third most significant pathway (Pcorrected=1.0610
25)
among the 159 enriched canonical pathways in the 1475 gene set.
The results for the Bio Function categories were too unspecific,
due to the large number of enriched categories reported for each
of the three gene lists (61 to 77 enriched terms) (Table 2).
However, the general categories cell death, cancer and cellular
growth and proliferation were among the top four enriched terms
in the three gene lists, with corrected P values between 10
24 and
10
220 (data not shown).
Enrichment analysis with all enrichment tools was also
performed individually for the four single GEP studies reporting
more than 100 unique mapped genes [13–16] (Table S7). From
the 18 GO/KEGG terms, the general GO categories were
reported only by some of the four individual GEP studies, while
the more specific KEGG pathways appeared to be more
commonly reported. In the GEP study from Bertucci et al. [14]
almost all 18 categories came out as overrepresented in the gene
list.
Discussion
The large number of published microarray studies on prognosis
of CRC, showing a very low overlap in results, has provided no
generally accepted gene expression profile for prediction of CRC
Table 1. Gene expression profiling studies on CRC prognosis included in the present study.
First author Ref. Year Platform Samples
Study
design
Reported gene
identifiers (IDs)
Unique, mapped
genes*
Agrawal [35] 2002 Affymetrix U95A 60 p.t. A 107 96
Arango [13] 2005 Affymetrix U133A 25 p.t. B 234 220
Bandres [36] 2007 Oligo array 16 p.t. A 8 6
Barrier (1) [28] 2005 Affymetrix U133A 12 p.t.+a.m. B 47 34
Barrier (2) [30] 2005 Affymetrix U133A 25 p.t.+a.m. B 100 94
Barrier (3) [29] 2006 Affymetrix U133A 50 p.t. B 30 20
Barrier (4) [31] 2007 Affymetrix U133A 24 p.t.+a.m. B 70 63
Bertucci [14] 2004 cDNA array 22 p.t.+a.m. A 290 234
Cavalieri [37] 2007 Agilent 1A 19 p.t. C 8 8
D’Arrigo [38] 2005 cDNA array 20 p.t. A 29 19
Eschrich [39] 2005 cDNA array 78 p.t. C 43 26
Fritzmann [15] 2009 Affymetrix U95A 41 p.t., 25 m. D 121 115
Garman [40] 2008 Affym. U95A/133A 52 p.t. B 50 45
Grade [41] 2007 Oligo array 73 p.t. A 68 66
Jiang [32] 2008 Affymetrix U133A 123 p.t. B 7 7
Jorissen [16] 2009 Affym. U133Plus 293 p.t. D 128 116
Ki [42] 2007 cDNA array 23 p.t.+m. D 46 43
Kleivi [43] 2007 Agilent 1A 18 p.t., 4 m. D 40 40
Komuro [44] 2005 cDNA array 89 p.t. A 62 60
Kwon [45] 2004 cDNA array 12 p.t. A 60 53
Liersch [46] 2009 cDNA array 30 p.t. B 20 15
Lin [47] 2007 Oligo array+Affym. 204 p.t. B 35 32
Smith [48] 2009 Affym. U133Plus 55 p.t. E 34 34
Wang [33] 2004 Affymetrix U133A 74 p.t. B 23 20
Watanabe (2) [49] 2009 Affym. U133Plus 36 p.t. B 45 30
Watanabe (1) [50] 2009 Affymetrix U133A 89 p.t. A 73 57
Yamasaki [51] 2007 cDNA array 32 p.t., 32 m. D 119 82
*Number of unique, annotated mapped genes obtained by converting the originally reported gene identifiers (IDs) in each single study to the official HUGO gene
symbol. p.t., primary tumours; a.m., adjacent mucosa; m., metastasis; A, metastasis yes/no; B, recurrence yes/no; C, survival; D, metastasis vs. primary tumours; E,
prognosis good/bad.
doi:10.1371/journal.pone.0018867.t001
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outcome in CRC have been published, but are now underway [3].
The heterogeneity in the GEP study design regarding the features
related to disease progression makes a consistent comparison of
results between the single studies very difficult [17]. Here, we
report the results of our approach, in which we used the largest
Table 2. Number of overrepresented GO and KEGG categories in the three gene lists for each of the tools used.
54 gene list 124 gene list 1475 gene list
Tool name BP MF KEGG BP MF KEGG BP MF KEGG
ConsensusPathDB n.a. n.a. 2 n.a. n.a. 2 n.a. n.a. 1
DAVID 0 0 0 0 1 0 95 13 5
FatiGO 1 0 n.a. 0 6 n.a. 53 4 n.a.
GATHER 0 n.a. 0 1 n.a. 0 11 n.a. 1
GeneCodis 26 17 8 54 35 21 115 80 116
GOTM 10 10 n.a. 10 10 n.a. 10 10 n.a.
g:Profiler 9 0 0 16 1 1 181 18 4
Ingenuity* 77 0 69 1 61 159
ToppFun 35 3 0 29 17 1 234 34 10
WebGestalt 40 12 13 40 25 34 40 40 136
Only categories significantly associated after correction for multiple testing (P value,0.05) is shown. BP, Gene Ontology Biological Process; MF, Gene Ontology
Molecular Function; KEGG, Kyoto Encyclopedia of Genes and Genomes. n.a., database not applicable.
*Results of the enrichment analysis using the Ingenuity software have to be considered separately, since the software makes use of its own databases, Top Bio Function
and Top Canonical Pathways.
doi:10.1371/journal.pone.0018867.t002
Table 3. Consistently enriched GO and KEGG categories.
ID Category
Number of
genes in
category 54 gene list 124 gene list 1475 gene list
GO Biological Process (8 tools) Tools Genes Tools Genes Tools Genes
GO:0008283 cell proliferation 1166 0 - 4 22 8 175
GO:0048518 positive regulation of biological process 2252 3 18 3 31 5 258
GO:0048522 positive regulation of cellular process 2050 3 18 3 30 5 243
GO:0042981 regulation of apoptosis 892 2 10 3 18 5 129
GO:0042127 regulation of cell proliferation 853 0 - 3 17 6 121
GO:0042221 response to chemical stimulus 1520 1 13 4 31 6 250
GO Molecular Function (7 tools)
GO:0015078 hydrogen ion transmembrane transporter activity 9 3 0- 3662 9
GO:0022890 inorganic cation transmembrane
transporter activity
2 1 6 0- 3653 6
GO:0015077 monovalent inorganic cation transmembrane
transporter activity
1 7 2 0- 3663 0
GO:0005515 protein binding 8184 3 38 5 80 6 843
GO:0051082 unfolded protein binding 1 1 3 441473 0
KEGG pathway (7 tools)
KEGG4512 ECM-receptor interaction 5 8 223542 4
KEGG4510 focal adhesion 1 3 5 232554 9
KEGG5016 Huntington’s disease 1 4 3 0- 2644 1
KEGG190 oxidative phosphorylation 2 0 3 125743 3
KEGG5200 pathways in cancer 2 4 1 242846 7
KEGG5012 Parkinson’s disease 1 0 9 0- 2543 4
KEGG5222 small cell lung cancer 6 5 0- 2342 3
In each case, the number of enrichment tools reporting the category as significantly overrepresented and the maximal number of genes from the category present in
the input gene list are indicated.
doi:10.1371/journal.pone.0018867.t003
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first time applied and compared several enrichment tools to the
extracted gene lists. This strategy allowed us to identify the
oxidative phosphorylation chain and the extracellular matrix
receptor interaction categories, as well as a general category
related to cell proliferation and apoptosis, as the only significantly
and consistently overrepresented pathways involved in CRC
progression.
In the first part of the study, we tried to overcome the lack of
reproducibility in the GEP studies on CRC prognosis by selecting
the genes reported in more than one study, in an attempt to reduce
false positive results. From a total of 1475 unique, annotated genes
identified in 23 independent GEP studies, 124 genes (8.4%) were
reported in at least two studies, and only 9 of them (0.6%) in three
studies, which give us a clear idea of the lack of reproducibility at
the individual gene level. This lack of reproducibility does not
seem to be caused by the different investigated features related to
cancer prognosis, since the proportion of genes reported by two
studies of the same class (2.8% for recurrence, 5.3% for metastasis
studies, and 0% for survival studies) was even lower than for all
studies together (8.4%). Unexpectedly, 70 out of these 124 genes
(56.5%) showed contrasting direction in expression change
between two single studies, while for the other 54 (43.5%) the
expression change was in the same direction, 19 up-regulated
(15.3%) and 35 down-regulated (28.2%). The proportion of up-
and down –regulated genes was approximately the same also
within each of the consistently enriched GO and KEGG
categories. The inconsistencies in the direction of differential
expression can be attributed to several factors: first, the large
number of false positives observed in microarray gene expression
studies [18]; second, overgeneralization of comparisons in meta-
analyses, especially related to experimental design and background
reference for expression; third, heterogeneity in the tissue samples
used in each study; and fourth, inaccurate results due to poor study
design [19]. However, a clear explanation for these discrepancies
is missing. Only one previous meta-analysis of ten GEP studies has
reported a list of 13 genes differentially expressed in CRC with
good versus bad prognosis, reported by at least two independent
studies [4]. A comparison with our results showed that eight of the
genes are also present in our 124 gene list, with the same direction
in expression change (IGF2, IQGAP1, YWHAH, DEK, TP53,
OAS1, RARB, and PDCD10), three of them (IGF2, TP53 and
RARB) belonging to the group of broad categories related to cell
proliferation and apoptosis. The other five genes reported by
Cardoso et al. were actually not present in one of the two GEP
studies mentioned in the meta-analysis.
The second part of our analysis made use of freely available
enrichment tools to detect which GO categories or KEGG
pathways were significantly overrepresented in the three gene sets
obtained from the 23 gene expression profiling studies (1475, 124
or 54 gene list). Here, we attempted to overcome the known
differences in the overrepresentation analysis results by using up to
ten different singular enrichment analysis (SEA or class I)
enrichment tools. We selected only those categories which were
reported to be overrepresented by several tools and in at least two
of the three gene lists as consistently enriched categories. Gene set
enrichment analysis tools (GSEA or class II) were not considered,
since they require a summarized biological value (e.g. expression
fold change) for each of the genes in the input, which was not
available for most of the studies. Recently developed modular
enrichment analysis tools (MEA or class III) consider inter-
relationships of GO terms, but they require relatively large gene
input lists for a biologically meaningful analysis [6], and this was
not the case in our study.
Figure 1. Bar chart of enrichment ratios for GO and KEGG categories in the three gene lists (54, 124, and 1475 genes). Ratio of
enrichment=number of observed divided by the number of expected genes from each GO or KEGG category in the gene list (according to
WebGestalt or, alternatively, DAVID or GOTM tools). GO BP, Gene Ontology Biological Process; GO MF, Gene Ontology Molecular Function; KEGG,
Kyoto Encyclopedia of Genes and Genomes.
doi:10.1371/journal.pone.0018867.g001
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18867Enrichment tools suffer from several limitations, which have
been described in detail elsewhere [6,7], and it is recommended
to test multiple tools, even if they have similar capabilities and
functions [7]. For example, it has been observed that for the
same input data, ten different ontological analysis programs
resulted in P values ranging several orders of magnitude for
some GO terms [7]; the same effect was observed in our study.
KEGG pathways represent relatively well-defined known
biological pathways, rather than the more broad GO categories.
The use of pathway classification tools is anyway not free of
difficulties [20]. A recent overrepresentation analysis of
pathways from genome-wide association study data also
reported differences in outcome between three of the pathway
enrichment tools we used (DAVID, GATHER and WebGestalt)
[20]. Factors that can cause these differences in results include:
the sources and versions of annotation files; the statistical model
applied for the enrichment analysis; the set of reference genes
against which the P values for each term in the results are
calculated; and the method of correction for multiple experi-
ments [21]. In our analysis, the whole genome was used as a
background reference, and a significance threshold of corrected
Pv a l u e ,0.05 was used in all analyses. Despite this uniformity in
the conditions used, we also observed a considerable variability
in the number of reported enriched categories and in the P
values. Thus, this variability can be attributed to the statistical
model applied for the enrichment analysis, to the method of
correction for multiple testing, andt od i f f e r e n c e si nt h ev e r s i o n s
of the GO and KEGG data sources used. However, and despite
this apparent variation, most of the enriched categories reported
by the more stringent tools were included in the ones reported
by those tools reporting a larger number of terms, demonstrat-
ing the utility of our study strategy. Thus, bioinformatic
enrichment tools are a powerful approach to identify biological
processes in high-throughput data analysis, but selection of
enriched categories based on only one enrichment tool appears
to be quite arbitrary.
Finally,afterapplicationofrigorousselectioncriteria,a totalof18
categories (11 GO terms and seven KEGG pathways) were
considered as consistently overrepresented in the gene lists extracted
from the 23 different GEP studies on CRC prognosis. In the 124
gene list, a very high overlap of genes among the 18 categories was
observed, reducing the number of categories with biological
significance to three clearly different groups. First, a very general
group related to cell proliferation, apoptosis and protein binding,
which included a high proportion of the genes from each of the
three gene sets. Second, and more interesting, the oxidative
phosphorylationchain,includingsevengenes(ATP5C1,ATP6AP1,
ATP6V1H,COX5B,COX6B1,NDUFA1,andUQCRC1)(Figure
S1), five of them shared with Huntington’s and Parkinson’s disease
KEGG categories. Already several decades ago, it was suggested
that impaired oxidative metabolism may cause malignant growth
[22]. This assumption, known as Warburg’s hypothesis, has been
rediscovered by a broad range of experimental approaches showing
interaction of mitochondrial metabolism and tumour growth
[23,24]. Added to that, germline mutations in the mitochondrial
succinate dehydrogenase (complex II of the oxidative phosphory-
lation chain) subunits SDHD, SDHC, and SDHB are a frequent
cause of paragangliomas of the head and neck and of phaeochro-
mocytomas [25]. Also Huntington’s and Parkinson’s disease, the
other two enriched KEGG pathways with genes from the oxidative
phosphorylation chain, are associated with mitochondrial dysfunc-
tion [26]. Third, both KEGG terms extracellular matrix receptor
interaction and focal adhesion included four common genes
(COL5A1, FN1, SPP1, and TNXB) (Figure S2). Specific interac-
tions of the extracellular matrix molecules control cellular activities
such as adhesion, differentiation, apoptosis and proliferation [27].
Thus, and based on the functional classes of the genes, they look
promisingfor studies aimed to investigate their possible influenceon
the prognosis of CRC. Especially, the KEGG pathways oxidative
phosphorylation, extracellular matrix receptor interaction and focal
adhesion may provide new targets for drug development. Six of the
23 independent GEP studies performed an enrichment analysis of
GO and/or KEGG categories with their list of differentially
expressed genes, in all cases using only one enrichment tool. Only
the GEP study from Jorissen et al. [16] reported two KEGG
pathways also reported in our analysis (ECM-receptor interaction
and focal adhesion). When we searched for overrepresented
categories in individual GEP studies, clear differences between the
studies were observed. Although terms of specific KEGG pathways
oxidative phosphorylation and extracellular matrix molecules were
commonly reported, the general GO terms reported in our global
approach were identified only by some of the studies. These results
showthat ourapproach of combiningthedataof 23 individual GEP
studies not only is able to identify the common pathways reported
by individual large studies, but it is also able to report novel
consistently overrepresented pathways, which may be lost in small
studies.
In conclusion, our pathway-based enrichment analysis of 23
independent gene expression profiling studies on prognosis of
CRC indicated the oxidative phosphorylation chain, the extracel-
lular matrix receptor interaction category, and a general category
related to cell proliferation and apoptosis as significantly and
consistently overrepresented prognostic categories for CRC. These
categories have been functionally clearly related with cancer
progression, and deserve further investigation. It would be of
special interest if future GEP studies performed in large sample
cohorts could validate our results and identify these categories as
classifiers for bad prognosis.
Materials and Methods
Gene expression profiling (GEP) studies
A total of 27 GEP studies for prognosis prediction of CRC
were included in the analysis (Table 1): the 16 GEP studies
named in two recent reviews [2,3], three additional studies
included in a meta-analysis [4], and eight more recent studies
(PubMed search from January 2009 till March 2010) not included
in the previous reviews/meta-analysis. Four of the 27 studies used
partially overlapping samples [28–31], and another study [32]
was actually a follow-up of a previous one [33], reducing the total
number of independent studies to 23. According to the
investigated feature related to disease progression, seven of the
studies were based on the existence of recurrence, thirteen on the
presence of metastasis, two on survival data, and one on a
combination of survival and recurrence data. Due to the
heterogeneous nature of the available data, no attempt was
made to perform quantitative meta-analyses.
Gene set collection
It has been reported that the type of gene identifier used to
specify the differentially regulated genes can potentially affect the
results of the subsequent analysis [21]. We used the official HUGO
gene symbol as a consistent identifier for the reported genes. If the
gene symbol was not reported in the GEP study, we used the
following tools to convert the reported identifiers into the gene
symbol: NetAffx from Affymetrix (www.affymetrix.com), Entrez-
Gene from NCBI (www.ncbi.nlm.nih.gov/gene/), and the Gene
ID conversion tool from the DAVID bioinformatics resources
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PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e18867[34]. In many cases, the number of gene identifiers (IDs) reported
by the GEP study did not actually correspond to the annotated
genes, but to probes on the expression array or GenBankIDs.
Added to that, several studies counted some genes more than once.
Therefore, the current number of annotated genes finally used was
lower than the one reported by the majority of the GEP studies
(Table 1).
Gene lists
The lists of annotated genes reported by each of the 23
independent GEP studies for prognosis of CRC included in the
analysis were combined in order to identify those genes reported in
two or more studies. Three different gene lists were considered for
the subsequent enrichment analysis: all unique, annotated genes
reported (1475 genes) (Table S2); those genes reported in at least
two GEP studies (124 genes) (Table S1); and the ones which
additionally showed the same direction in gene expression change,
either up- or down-regulation, in two GEP studies (54 genes)
(Table S1).
Enrichment analysis
We performed enrichment analyses using the databases
GO (Biological Process and Molecular Function) and KEGG
pathways. For all enrichment tools, the input gene set consisted
of the 1475 gene list, the 124 gene list, or the 54 gene list,
respectively.
Ten enrichment software tools (see URLs) were selected based
on their freeware availability, their frequent appearance in
recent publications and their user-friendly application. Default
options were applied in all tools, with a significance threshold of
0.05 for adjusted P value, at least two genes from the input list in
the enriched category, and the whole genome as a reference
background. For GATHER, the recommended ln(Bayes factor)
.6 was used as significance threshold. The Ingenuity software
makes use of its own two databases, Top Bio Function and Top
Canonical Pathways, which however are comparable with the
GO and the KEGG databases, respectively, used by the other
enrichment tools. Key statistical and multiple testing correction
methods used by each tool are shown in Table S8.
Consistently enriched categories
Only the GO or KEGG categories reported to be significantly
enriched by several enrichment tools in a gene list were considered
as consistently overrepresented. In an attempt to select only top-
ranked categories, we took into account the size differences
between GO and KEGG categories as well as the differences in
the number of categories reported by each tool. The number of
tools established as a threshold was, for each gene list and GO or
KEGG databases, the one reporting at least five common enriched
categories for that number of tools (Table S6). For both the 54 and
the 124 gene list, the threshold was three enrichment tools for GO
Biological Process and Molecular Function, and two enrichment
tools for KEGG pathways. For the 1475 gene list, the threshold
was five enrichment tools for GO Biological Process and
Molecular Function, and four enrichment tools for KEGG
pathways (Table S6). Since the three gene lists are related (the
54 gene list is included in the 124 gene list, which is part of the
1475 gene list), we additionally selected the categories reported to
be enriched in the large 1475 gene list and at least one of the other
two lists. With this double filter, we guaranteed that the survived
enriched categories are the ones consistently enriched in the GEP
studies on prognosis of CRC.
Supporting Information
Figure S1 Representation of the KEGG oxidative phosphory-
lation pathway (map00190), with the seven genes from the 124
gene list indicated in red, as well as the location of the four
complexes in the mitochondrial electron-transport chain to which
they belong.
(TIF)
Figure S2 Representation of the KEGG ECM-receptor inter-
action category (map04512), with location of the fives genes from
the 124 gene list indicated in red.
(TIF)
Table S1 124 genes reported in at least two gene expression
profiling studies on CRC prognosis.
(DOC)
Table S2 1475 unique, annotated genes reported in 23
independent gene expression profiling studies on CRC prognosis.
(DOC)
Table S3 Results of all enrichment tools used with the 54 gene
list. Only those categories selected by at least two enrichment tools
are shown. In each case, the first row represents the overrepre-
sentation P value adjusted for multiple testing, and the second row
the number of genes in the category within the 54 gene list. Table
S3A. Results for Gene Ontology Biological Process categories;
Table S3B. Results for Gene Ontology Molecular Function
categories; Table S3C. Results for KEGG pathway categories.
(DOC)
Table S4 Results of all enrichment tools used with the 124 gene
list. Only those categories selected by at least two enrichment tools
are shown. In each case, the first row represents the overrepre-
sentation P value adjusted for multiple testing, and the second row
the number of genes in the category within the 124 gene list. Table
S4A. Results for Gene Ontology Biological Process categories;
Table S4B. Results for Gene Ontology Molecular Function
categories; Table S4C. Results for KEGG pathway categories.
(DOC)
Table S5 Results of all enrichment tools used with the 1475 gene
list. Only those categories selected by at least two enrichment tools
are shown. In each case, the first row represents the overrepre-
sentation P value adjusted for multiple testing, and the second row
the number of genes in the category within the 1475 gene list.
Table S5A. Results for Gene Ontology Biological Process
categories; Table S5B. Results for Gene Ontology Molecular
Function categories; Table S5C. Results for KEGG pathway
categories.
(DOC)
Table S6 Number of overrepresented GO and KEGG catego-
ries reported by more than one enrichment tool.
(DOC)
Table S7 Result of the enrichment analysis in four individual
GEP studies for the consistently enriched GO and KEGG
categories of the global analysis.
(DOC)
Table S8 Enrichment tools used and their characteristics.
(DOC)
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